Zomedica Q3 2022 Earnings Report
Key Takeaways
Zomedica reported a strong third quarter with revenue reaching $4.78 million, a 75% gross margin, and closed the quarter with $158.49 million in cash, cash equivalents, and available-for-sale securities. The company experienced revenue growth driven by both organic sales and recent acquisitions.
Total revenue for the third quarter 2022 was $4.78 million, compared to $0.02 million in the third quarter of 2021.
Gross margin was 75%.
Therapeutic segment revenue from PulseVet and Assisi was approximately $4.68 million in the third quarter of 2022, an increase of approximately 15% over their 2021 revenue for the same period of $4.07 million as standalone companies.
Zomedica ended the third quarter with $158.49 million in cash, cash equivalents, and available for sale securities.